Following his recent publication in the Lancet Respiratory Medicine, and presentation at the ERS Congress, we spoke with Prof. Liam Heaney (Queen’s University, Belfast, Northern Ireland, UK) about the composite biomarker approach to optimising steroid dosage in patients with severe asthma.
- Why is there a need for new approaches to optimising steroid dosage in people with severe asthma? (0:11)
- Could you give us a brief overview of the composite biomarker approach to optimising steroid dosage? (1:06)
- Could you tell us a little about your recent study comparing this approach with a symptomatic/risk/based algorithm? (2:23)
- What were the major findings of this study in terms of clinical and patient-reported outcomes? (4:19)
- What will be the impact of these findings on clinical practice and what future studies are planned? (6:10)
Speaker disclosure: Liam Heaney has received grant funding and taken part in advisory boards and given lectures at meetings supported by Hoffmann-La Roche–Genentech and Aerocrine. He has also taken part in asthma clinical trials sponsored by Hoffmann-La Roche–Genentech, and is an Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma, which involves industrial partnerships with a number of pharmaceutical companies, including Hoffman-La Roche and Aerocrine.
Support: Interview and filming supported by Touch Medical Media. Niche Science and Technology were given the opportunity to review the video. No changes to the video were made as a result.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In Asthma
Michael Wechsler, ERS 2020 – Dupilumab in the LIBERTY ASTHMA TRAVERSE Trial
We discuss with Michael Wechsler (National Jewish Health, Denver, CO, USA) the clinical evidence supporting the use of dupilumab in patients with asthma and specifically the major findings from the long-term safety evaluation of dupilumab in the LIBERTY ASTHMA TRAVERSE trial (NCT02134028). Questions 1. What are the major unmet needs in the biologic treatment of […]
Richard van Zyl-Smit, ERS 2020 – Optimising Inhaled Therapies for Asthma
Richard van Zyl-Smit (University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa) kindly took the time to speak with us about maximising the benefit of inhaler therapy and recent development being made in this field. Questions What are the major unmet needs in the use of inhaled therapies for the control of […]
Peter J Barnes, ERS 2020 – Smart Inhalers for COPD and Asthma
During the ERS International Congress 2020, it was great to catch up with our Editorial Board member, Prof. Peter J Barnes (Imperial College, London, UK), to continue the discussion around Smart Inhalers and how they could help optimise inhaler use in patients. Questions How common is poor adherence and inhaler technique in people with asthma […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!